Elad Sharon, MD, MPH, joined the NCI Cancer Therapy Evaluation Program (CTEP) in December 2011 as a Medical Officer in the Investigational Drug Branch, where he works with academia and industry to develop promising new cancer therapies. His portfolio includes antibody-drug conjugates, immune checkpoint inhibitors and other agents. Dr. Sharon co-directs immunotherapy trials at CTEP and serves as an attending physician in NCI's Developmental Therapeutics Clinic.